Safety and efficacy of novel oblique-viewing scope for B2-endoscopic ultrasound-guided hepaticogastrostomy.

IF 2.1 Q3 GASTROENTEROLOGY & HEPATOLOGY

Clinical Endoscopy Pub Date : 2024-07-01 Epub Date: 2024-03-29 DOI:10.5946/ce.2023.129

Sho Ishikawa, Kazuo Hara, Nozomi Okuno, Nobumasa Mizuno, Shin Haba, Takamichi Kuwahara, Yasuhiro Kuraishi, Takafumi Yanaidani, Masanori Yamada, Tsukasa Yasuda, Toshitaka Fukui, Teru Kumagi, Yoichi Hiasa

{"title":"Safety and efficacy of novel oblique-viewing scope for B2-endoscopic ultrasound-guided hepaticogastrostomy.","authors":"Sho Ishikawa, Kazuo Hara, Nozomi Okuno, Nobumasa Mizuno, Shin Haba, Takamichi Kuwahara, Yasuhiro Kuraishi, Takafumi Yanaidani, Masanori Yamada, Tsukasa Yasuda, Toshitaka Fukui, Teru Kumagi, Yoichi Hiasa","doi":"10.5946/ce.2023.129","DOIUrl":null,"url":null,"abstract":"Background/aims: Endoscopic ultrasound (EUS)-guided hepaticogastrostomy (EUS-HGS) performed at the intrahepatic bile duct segment 3 (B3) is widely used for biliary drainage. Although performing post-puncture procedures is easier in the intrahepatic bile duct segment 2 (B2) when using a conventional oblique-viewing (OV) EUS scope, this method may cause transesophageal puncture and severe adverse events. We evaluated the safety and efficacy of B2 puncture using a novel OV-EUS scope.Methods: In this single-center retrospective study, we prospectively enrolled and collected data from 45 patients who consecutively underwent EUS-HGS procedures with a novel OV-EUS scope between September 2021 and December 2022 at our cancer center.Results: The technical success rates of B2-EUS-HGS and EUS-HGS were 93.3% (42/45) and 97.8% (44/45), respectively. The early adverse event rate was 8.9% (4/45) with no cases of scope changes or transesophageal punctures. The median procedure time was 13 minutes (range, 5-30).Conclusions: B2-EUS-HGS can be performed safely with the novel EG-740UT (Fujifilm) OV-scope without transesophageal puncture and with a high success rate. B2-EUS-HGS using this novel OV scope may be the preferred strategy for EUS-HGS.","PeriodicalId":10351,"journal":{"name":"Clinical Endoscopy","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11294849/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Endoscopy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5946/ce.2023.129","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/29 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aims: Endoscopic ultrasound (EUS)-guided hepaticogastrostomy (EUS-HGS) performed at the intrahepatic bile duct segment 3 (B3) is widely used for biliary drainage. Although performing post-puncture procedures is easier in the intrahepatic bile duct segment 2 (B2) when using a conventional oblique-viewing (OV) EUS scope, this method may cause transesophageal puncture and severe adverse events. We evaluated the safety and efficacy of B2 puncture using a novel OV-EUS scope.

Methods: In this single-center retrospective study, we prospectively enrolled and collected data from 45 patients who consecutively underwent EUS-HGS procedures with a novel OV-EUS scope between September 2021 and December 2022 at our cancer center.

Results: The technical success rates of B2-EUS-HGS and EUS-HGS were 93.3% (42/45) and 97.8% (44/45), respectively. The early adverse event rate was 8.9% (4/45) with no cases of scope changes or transesophageal punctures. The median procedure time was 13 minutes (range, 5-30).

Conclusions: B2-EUS-HGS can be performed safely with the novel EG-740UT (Fujifilm) OV-scope without transesophageal puncture and with a high success rate. B2-EUS-HGS using this novel OV scope may be the preferred strategy for EUS-HGS.

查看原文本刊更多论文

B2-内镜超声引导肝胃造口术中新型斜视镜的安全性和有效性。

背景/目的：在肝内胆管第 3 段（B3）进行的内镜超声（EUS）引导肝胃造口术（EUS-HGS）被广泛用于胆道引流。虽然在肝内胆管 2 段（B2）使用传统的斜视（OV）EUS 镜更容易进行穿刺后手术，但这种方法可能会导致经食道穿刺和严重的不良事件。我们评估了使用新型 OV EUS 镜进行 B2 段穿刺的安全性和有效性：在这项单中心回顾性研究中，我们对 2021 年 9 月至 2022 年 12 月期间在本癌症中心使用新型 OV-EUS 镜连续进行 EUS-HGS 手术的 45 例患者进行了前瞻性登记和数据收集：B2-EUS-HGS和EUS-HGS的技术成功率分别为93.3%（42/45）和97.8%（44/45）。早期不良事件发生率为 8.9%（4/45），无镜体改变或经食道穿刺病例。中位手术时间为 13 分钟（5-30 分钟不等）：结论：使用新型 EG-740UT（富士胶片）OV-scope 可以安全地进行 B2-EUS-HGS，无需经食道穿刺，且成功率高。使用这种新型 OV 镜进行 B2-EUS-HGS 可能是 EUS-HGS 的首选策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Endoscopy GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

4.40

自引率

8.00%

发文量

审稿时长

26 weeks